NIKKEI 225
27,819.33 -180.63 (-0.65%) HANG SENG
19,986.62 +375.78 (+1.92%) CRUDE OIL
91.77 -0.16 (-0.17%) GOLD FUTURES
1,802.20 -11.50 (-0.63%) DOW
33,309.51 +535.11 (+1.63%) BTC-GBP
19,976.20 +1,112.47 (+5.90%)
Silence Therapeutics plc (SLNCF)
| Previous close | 29.85 |
| Open | 29.85 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 29.85 - 29.85 |
| 52-week range | 2.50 - 29.85 |
| Volume | |
| Avg. volume | 67 |
| Market cap | 2.68B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Silence Therapeutics to Present at Jefferies Healthcare Conference
LONDON, June 02, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. EDT / 2:00 p.m. GMT.
- Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
LONDON, May 18, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, on May 23-26, 2022.
- Business Wire
Silence Therapeutics Reports First Quarter 2022 Results
LONDON, May 16, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today reported its financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.
